Axcella to Present at BioCentury’s 24th Annual Future Leaders in the Biotech Industry Conference

CAMBRIDGE, Mass.–(BUSINESS WIRE)– Axcella, a biotechnology company pioneering transformative medicines for
patients with severe conditions caused by disrupted amino acid biology,
announced today that Robert Connelly, President and Chief Executive
Officer, will present a company overview at the 24^th Annual
Future Leaders in the Biotech Industry investment conference in New
York, NY. The presentation will take place at the Millennium Broadway
Hotel & Conference Center on April 7, 2017, at 2 p.m. EDT in room
402/403, and will be followed by a Q&A breakout session at 2:30 p.m. EDT.

About Axcella
Axcella is pioneering a revolutionary
therapeutic modality that identifies how disturbances in amino acid
biology lead to disease. The company’s platform rapidly yields novel
molecules to restore normal amino acid homeostasis, treat disease and
reactivate healthy central metabolism. Axcella has expeditiously
translated its discoveries into molecules that have been tested in 10
clinical trials to date, with lead programs in intractable epilepsy,
NASH and pathological atrophy. Its lead clinical candidates have
demonstrated in human and preclinical models an ability to bring
homeostasis to dysregulated cells, repair cellular function, restore
healthy pathways, and regenerate tissue and healthy organ function. The
company was founded by VentureLabs, the Innovation Foundry at Flagship
Pioneering, and has received financing from Flagship’s venture funds,
alongside co-investors Fidelity Research & Management Group, Gurnet
Point Capital and Nestlé Health Science. Axcella is based in Cambridge,
Mass. For more information, visit www.axcellahealth.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170405005335/en/